San Francisco Chronicle (08.29.03) - Wednesday, September 03,
In August, South Africa's government announced it would
finally begin offering antiretroviral (ARV) drugs to its
citizens with AIDS, but some experts warn that drug-resistant
strains of HIV may proliferate if the program is not managed
properly. Dr. Robert Gallo, the co-discoverer of HIV, said:
"The attitude seems to be that resistance is understandable
and a part of life." Unfettered access to AIDS drugs could
lead to "multiple drug- resistant mutants of HIV which become
epidemic and cause new kinds of epidemics in the future," said
Gallo, who supports South Africa's program.
In parts of the world where ARV drugs have been used most,
such as the United States and Europe, 10-15 percent of all new
HIV infections show at least some drug-resistant mutations.
And conditions are ripe for the development of HIV mutations
in developing nations because of the chaotic drug delivery
process.
"In every African city, these medications are available to the
open market," said Dr. Paul Farmer, professor of social
medicine at Harvard University. "What's going on now is called
'therapeutic anarchy.'" Many stop taking drugs when their
funds run out and continue when they have saved enough to buy
more, a "recipe for disaster." Farmer said those who focus on
the threat of resistance share some of the blame for that
chaos. "In repeating the drug resistance mantra, they have
slowed down the aggressive interventions that might deliver
these drugs regularly to those who need them most, not merely
those who can pay for them."
With generic medications available in parts of the continent
and donations from drug companies, ARV drugs now cost only $1
a day in Africa. But HIV is quick to mutate, and once it does,
it must be attacked with ever more expensive drugs. In the
United States, each resistance test costs $350 to $500, a
fortune in South Africa, where per capita government health
expenditure is $108 per year. However, when only 50,000 people
in sub-Saharan Africa with AIDS receive ARV drugs, resistance
is not yet a major issue.
www.aegis.org